# Japan Nontuberculous Mycobacteria Market

> Japan Nontuberculous Mycobacteria Market Research Report: Size, Share, Trend Analysis By Class of Drugs (Oral Antibiotics, IV Antibiotics, Anti Nausea, Nebulized Antibiotics) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 2.79%
- **2024:** $ 350.55 Million
- **2025:** $ 360.33 Million
- **2035:** $ 474.3 Million
- **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Becton Dickinson and Company (US), F. Hoffmann-La Roche AG (CH), bioMérieux SA (FR), Qiagen N.V. (NL), Hologic, Inc. (US)

**Report ID:** MRFR/HC/50864-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/japan-nontuberculous-mycobacteria-market-52623

---

## Market Summary

## **Japan Nontuberculous Mycobacteria Market Overview**

As per MRFR analysis, the Japan Nontuberculous Mycobacteria Market Size was estimated at 364.88 (USD Million) in 2023. The Japan Nontuberculous Mycobacteria Market Industry is expected to grow from 374(USD Million) in 2024 to 490 (USD Million) by 2035. The Japan Nontuberculous Mycobacteria Market CAGR (growth rate) is expected to be around 2.486% during the forecast period (2025 - 2035).

**Key Japan Nontuberculous Mycobacteria Market Trends Highlighted**

The Japan Nontuberculous Mycobacteria market is experiencing significant trends driven by an increasing awareness about the prevalence of nontuberculous mycobacterial infections among the population. The Japanese government has been proactive in addressing public health concerns, leading to enhanced research funding for infectious diseases and better diagnostic tools. This increase in government initiatives is a key market driver, as it facilitates the development of more effective therapies, thus driving demand within the sector.

Recent times have seen advancements in molecular diagnostics that significantly improve the detection rates of nontuberculous mycobacteria.The shift towards rapid testing methods supports quicker treatment initiation, reflecting the need for timely and accurate diagnosis in the healthcare system. In Japan, hospitals and laboratories are investing in updated equipment and training staff to effectively utilize these new testing methods. Furthermore, there is a clearer focus on patient education and preventive measures, encouraging individuals to seek medical attention promptly. Opportunities to explore include the growing emphasis on personalized medicine and tailored treatment approaches that cater to individual patient profiles.

This trend aligns with Japan's high standard of healthcare, as personalized therapies can lead to improved patient outcomes. Additionally, partnerships between local biotech firms and research institutions can foster innovation in drug development targeting nontuberculous mycobacteria, tapping into the evolving landscape of the healthcare market in Japan. Overall, the combination of increasing awareness, government initiatives, and technological advancements presents a dynamic environment for the Nontuberculous Mycobacteria market in Japan.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Japan Nontuberculous Mycobacteria Market Drivers**

**Increasing Incidence of Respiratory Infections**

Rising incidence of respiratory infections, particularly those caused by nontuberculous mycobacteria (NTM), is a major driving force in Japan Nontuberculous Mycobacteria Market Industry. According to Japan's Ministry of Health, Labor, and Welfare, the frequency of respiratory infections has continuously increased, with recorded instances of NTM infections increasing by around 12% in the last five years. This rising incidence can be ascribed to a variety of variables, including aging demographics and environmental issues, particularly in metropolitan areas where air pollution is a concern.

The Japanese government is aggressively raising awareness through public health initiatives, resulting in increased demand for diagnostic tools and therapy choices to address NTM disorders.

**Advancements in Diagnostic Technologies**

The innovation and development of advanced diagnostic technologies for detecting nontuberculous mycobacteria are significantly contributing to the growth of the Japan Nontuberculous Mycobacteria Market Industry. Recent initiatives by Japanese companies such as Fujifilm and Olympus Corporation have led to the introduction of more efficient molecular diagnostic tests that provide quicker results.

The Ministry of Health, Labor and Welfare has endorsed these developments in its recent guidelines, emphasizing the importance of early detection in improving treatment outcomes.These advancements in technology not only facilitate detection but also enhance the overall understanding of the prevalence of NTM in the population, thereby driving investment in this market.

**Rising Awareness and Education Initiatives**

Improved awareness and education regarding nontuberculous mycobacteria pose a significant driver in the Japan Nontuberculous Mycobacteria Market Industry. In recent years, both governmental bodies and private health organizations have increased efforts to inform healthcare professionals and the general public about the risks associated with NTM. 
According to reports from the Japan Association for Infectious Diseases, awareness programs have led to a 20% increase in screening for NTM in healthcare settings.This surge in awareness results in more individuals seeking medical consultations, thereby translating into increased demand for diagnostic and therapeutic solutions tailored to treating NTM infections.

**Japan Nontuberculous Mycobacteria Market Segment Insights**

**Nontuberculous Mycobacteria Market Class of Drugs Insights**

The Class of Drugs segment within the Japan Nontuberculous Mycobacteria Market plays a crucial role in the treatment and management of infections caused by non-tuberculous mycobacteria, which have been gaining recognition due to their growing prevalence. Within this segment, Oral Antibiotics are often preferred for their ease of administration and convenience, making them an essential component in outpatient settings. On the other hand, IV Antibiotics provide a more aggressive approach for severe cases, highlighting the need for flexible treatment options to cater to both mild and severe infections.

The Anti Nausea medications are essential in managing side effects associated with antibiotic treatments, ensuring better patient adherence to therapy. Nebulized Antibiotics represent a significant innovation in treatment delivery, particularly for patients who may struggle with oral or intravenous routes, offering a targeted approach to lung infections, which have been prevalent in Japan.

The increasing aging population in Japan, coupled with a rise in chronic lung conditions, drives the demand for more sophisticated treatment methods within this segment.The diversity in administration routes also reflects the evolving nature of patient care, focusing on personalized treatment plans that cater to individual patient needs. Additionally, with advancements in pharmaceutical technologies, the efficacy and safety profile of drugs in this class continue to improve, providing further opportunities for growth in the Japan Nontuberculous Mycobacteria Market.

Overall, the Class of Drugs segment not only showcases the pivotal role that antibiotics play in managing difficult infections but also emphasizes the continuous need for research and development in this area to overcome existing challenges and explore new therapeutic options.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Japan Nontuberculous Mycobacteria Market Key Players and Competitive Insights**

The Japan Nontuberculous Mycobacteria Market is characterized by a diverse array of players focused on addressing the growing prevalence of infections caused by nontuberculous mycobacteria (NTM). This segment is witnessing increased attention due to rising awareness of the clinical significance of NTM infections, particularly among patients with underlying health conditions. The competitive landscape shows a mix of established pharmaceutical companies and emerging biotechnology firms, each striving to innovate and enhance their product offerings. The market dynamics are influenced by factors such as regulatory environments, advances in diagnostic technologies, and the evolving treatment paradigms for NTM infections.

As a result, companies are constantly seeking to strengthen their market position through strategic partnerships, research and development investments, and leveraging their clinical expertise to meet the emerging demands of healthcare providers and patients in Japan. Kyowa Kirin holds a significant position in the Japan Nontuberculous Mycobacteria Market, known for its commitment to addressing unmet medical needs through innovative therapies and an extensive research portfolio. The company has established a strong presence in Japan, emphasizing the development of targeted treatments for NTM infections.

Its strengths include a robust pipeline of products that leverage advanced drug delivery techniques and significant investments in clinical trials that showcase the efficacy of their therapies in combating NTM. The company's deep understanding of the Japanese healthcare system and patient demographics further enhances its ability to tailor solutions that meet the specific needs of healthcare professionals and patients alike.

Moreover, its strong collaborations with academic institutions and research organizations add to its competitive edge, enabling access to cutting-edge scientific insights and fostering innovation in this niche market.Daiichi Sankyo plays a critical role in the Japan Nontuberculous Mycobacteria Market through its dedicated focus on developing and delivering innovative solutions for the diagnosis and treatment of infections. The company manufactures a range of key products aimed at addressing the complexities associated with NTM, highlighting its commitment to advancing therapeutics in this field.

Daiichi Sankyo's strong market presence is bolstered by its established relationships with healthcare providers and its continuous investment in research and development efforts. Notably, the company has engaged in strategic mergers and acquisitions, which have strengthened its portfolio and expanded its capabilities in delivering effective therapies for NTM infections. The integration of new technologies and the enhancement of existing drug formulations position Daiichi Sankyo as a formidable competitor in Japan's market, reinforcing its role in the fight against nontuberculous mycobacterial diseases.

**Key Companies in the Japan Nontuberculous Mycobacteria Market Include**

- Kyowa Kirin
- Daiichi Sankyo
- Nippon Chemiphar
- Eisai
- Kissei Pharmaceutical
- Otsuka Pharmaceutical
- Takeda Pharmaceutical
- Hokko Chemical
- Fujifilm Holdings
- Mitsubishi Tanabe Pharma
- Astellas Pharma
- Asahi Kasei Pharma
- Hirofumi Healthcare

**Japan Nontuberculous Mycobacteria Market Industry Developments**

The Japan Nontuberculous Mycobacteria Market has seen significant developments recently, particularly in terms of growth and strategic ventures. Companies such as Kyowa Kirin and Takeda Pharmaceutical have been enhancing their Research and Development efforts, leading to innovative treatment options for infections caused by non-tuberculous mycobacteria. In August 2023, Daiichi Sankyo announced a collaboration focused on developing therapies targeting chronic respiratory diseases associated with nontuberculous mycobacteria.

The market has also been influenced by mergers and acquisitions, with Eisai acquiring a minority stake in a biotech firm aimed at leveraging combinations of therapies to tackle these infections, which was publicly announced in July 2023. In terms of market valuation, the Japan Nontuberculous Mycobacteria Market has seen increased investment, reflecting an overall growth trend, which is expected to further diversify treatment options and improve patient outcomes. Additionally, the Japanese government has been prioritizing research funding to combat rare infectious diseases, thus bolstering the overall market landscape.

A significant development from two years ago was Fujifilm Holdings' announcement in September 2021 regarding the initiation of clinical trials for a novel treatment targeting nontuberculous mycobacteria, further indicating progress in addressing this health concern.

**Japan Nontuberculous Mycobacteria Market Segmentation Insights**

**Nontuberculous Mycobacteria Market Class of Drugs****Outlook**

- Oral Antibiotics
- IV Antibiotics
- Anti Nausea
- Nebulized Antibiotics

## Market Drivers

### Rising Healthcare Expenditure

The rising healthcare expenditure in Japan is a significant driver for the nontuberculous mycobacteria market. As the population ages and the prevalence of chronic diseases increases, healthcare spending is expected to rise, leading to greater investment in diagnostic and therapeutic solutions for nontuberculous mycobacterial infections. This trend is reflected in the increasing budgets allocated to hospitals and healthcare facilities for advanced diagnostic technologies and treatment options. Moreover, the willingness of patients to invest in their health is likely to drive demand for effective therapies, thereby expanding the market. The overall increase in healthcare expenditure may create a favorable environment for the growth of the nontuberculous mycobacteria market.

### Advancements in Research and Development

Ongoing advancements in research and development are significantly influencing the nontuberculous mycobacteria market. Japanese research institutions and pharmaceutical companies are increasingly focusing on understanding the pathogenic mechanisms of nontuberculous mycobacteria, which may lead to the discovery of novel therapeutic agents. The investment in R&D is expected to enhance the development of targeted therapies and improve diagnostic accuracy. Furthermore, the collaboration between academia and industry is fostering innovation, potentially resulting in new treatment modalities that could capture a larger share of the market. This emphasis on R&D is likely to drive growth and expand the therapeutic landscape for nontuberculous mycobacterial infections.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is emerging as a significant driver for the nontuberculous mycobacteria market. In Japan, healthcare providers are increasingly recognizing the importance of tailoring treatments to individual patient profiles, particularly for complex infections caused by nontuberculous mycobacteria. This trend is supported by advancements in genomic technologies and biomarker identification, which enable more precise diagnostics and treatment plans. As a result, the market is likely to see a rise in demand for personalized therapeutic options, which could enhance treatment efficacy and improve patient adherence. The integration of personalized medicine into clinical practice may reshape the competitive landscape of the nontuberculous mycobacteria market.

### Increasing Incidence of Respiratory Diseases

The rising incidence of respiratory diseases in Japan is a crucial driver for the nontuberculous mycobacteria market. Reports indicate that respiratory infections, including those caused by nontuberculous mycobacteria, have been on the rise, leading to increased healthcare costs and a greater demand for effective diagnostic and therapeutic solutions. The prevalence of conditions such as chronic obstructive pulmonary disease (COPD) and bronchiectasis, which can be exacerbated by nontuberculous mycobacterial infections, is contributing to this trend. As healthcare providers seek to address these challenges, The nontuberculous mycobacteria market is likely to experience growth. This growth will emphasize innovative treatment options and improved patient outcomes.

### Increased Government Funding for Infectious Disease Research

In Japan, increased government funding for infectious disease research is playing a pivotal role in shaping the nontuberculous mycacteria market. The government has recognized the need to address the growing burden of infectious diseases, including those caused by nontuberculous mycobacteria. This funding is directed towards enhancing research capabilities, developing new diagnostic tools, and supporting clinical trials for innovative therapies. As a result, the market is likely to benefit from a more robust research infrastructure, leading to accelerated product development and improved healthcare outcomes. The commitment to funding infectious disease research may also attract private investment, further stimulating growth in the nontuberculous mycobacteria market.

## Future Outlook

The [Nontuberculous Mycobacteria Market](https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170) in Japan is projected to grow at a 2.79% CAGR from 2025 to 2035, driven by increasing awareness and advancements in diagnostic technologies.

**New opportunities:**

- Development of targeted therapies for specific nontuberculous mycobacterial infections.
- Expansion of telehealth services for remote patient monitoring and consultations.
- Investment in advanced diagnostic tools to enhance early detection and treatment efficacy.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Class of Drugs: IV Antibiotics (Largest) vs. Oral Antibiotics (Fastest-Growing)

In the Japan nontuberculous mycobacteria market, the class of drugs segment is diverse, with IV Antibiotics holding the largest market share due to their effectiveness in treating severe infections. These drugs are widely recognized for their reliability and high efficacy, making them the preferred choice among healthcare professionals. In contrast, Oral Antibiotics are witnessing a rapid increase in adoption, driven by their ease of administration and patient compliance, positioning them as a notable competitor in the market.

The growth trends within this segment are influenced by various factors, including an uptick in nontuberculous mycobacterial infections and advancements in drug formulations. As healthcare providers increasingly seek less intrusive treatment methods, Oral Antibiotics are becoming more prominent. Additionally, the demand for IV Antibiotics remains strong, attributable to their critical role in serious cases requiring immediate intervention. This dynamic interplay between the segments highlights the evolving landscape of treatment options.

IV Antibiotics (Dominant) vs. Oral Antibiotics (Emerging)

IV Antibiotics are established as the dominant segment within the Japan nontuberculous mycobacteria market, primarily due to their targeted approach in treating severe infections effectively. They are preferred in hospital settings for immediate, intensive care. However, Oral Antibiotics are emerging rapidly, appealing to patients seeking convenience and less invasive treatment options. Their favorable compliance rates and evolving formulations enhance their market position. As healthcare continues to shift towards outpatient settings, the growth potential for Oral Antibiotics is significant. This dual presence of dominant IV Antibiotics and emerging Oral Antibiotics shapes the market's future, emphasizing the need for a balanced approach in treatment strategies to cater to diverse patient needs.

## Competitive Benchmarking

The nontuberculous mycobacteria market in Japan is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key growth drivers include the rising prevalence of nontuberculous mycobacterial infections and advancements in diagnostic technologies. Major players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Abbott Laboratories (US) are actively positioning themselves through a combination of product innovation and regional expansion. Their operational focus appears to be on enhancing diagnostic capabilities and improving patient outcomes, which collectively fosters a dynamic competitive environment.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market seems moderately fragmented, with several key players exerting influence through differentiated product offerings and strategic collaborations. This fragmentation allows for a variety of approaches to market entry and expansion, which can be advantageous in addressing diverse customer needs.
In October 2025, Thermo Fisher Scientific (US) announced the launch of a new diagnostic platform specifically designed for the rapid detection of nontuberculous mycobacteria. This strategic move is likely to enhance their market share by providing healthcare professionals with faster and more accurate diagnostic tools, thereby improving patient management. The introduction of this platform underscores the company's commitment to innovation and its focus on addressing unmet clinical needs in the region.
In September 2025, Merck KGaA (DE) expanded its collaboration with local Japanese healthcare providers to enhance the accessibility of its diagnostic solutions. This partnership is expected to facilitate the integration of advanced diagnostic technologies into clinical practice, potentially leading to improved patient outcomes. By strengthening its local presence, Merck KGaA is likely to solidify its competitive position in the market, demonstrating the importance of regional partnerships in driving growth.
In August 2025, Abbott Laboratories (US) launched a new line of molecular diagnostic tests aimed at detecting nontuberculous mycobacteria in respiratory samples. This initiative not only reflects Abbott's focus on innovation but also highlights the growing trend towards personalized medicine in infectious disease management. The strategic importance of this launch lies in its potential to provide healthcare providers with more precise diagnostic tools, thereby enhancing treatment efficacy and patient care.
As of November 2025, current competitive trends in the nontuberculous mycobacteria market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostic processes. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative solutions that address specific clinical needs.

## Recent News & Developments

The Japan Nontuberculous Mycobacteria Market has seen significant developments recently, particularly in terms of growth and strategic ventures. Companies such as Kyowa Kirin and Takeda Pharmaceutical have been enhancing their Research and Development efforts, leading to innovative treatment options for infections caused by non-tuberculous mycobacteria. In August 2023, Daiichi Sankyo announced a collaboration focused on developing therapies targeting chronic respiratory diseases associated with nontuberculous mycobacteria.

The market has also been influenced by mergers and acquisitions, with Eisai acquiring a minority stake in a biotech firm aimed at leveraging combinations of therapies to tackle these infections, which was publicly announced in July 2023. In terms of market valuation, the Japan Nontuberculous Mycobacteria Market has seen increased investment, reflecting an overall growth trend, which is expected to further diversify treatment options and improve patient outcomes. Additionally, the Japanese government has been prioritizing research funding to combat rare infectious diseases, thus bolstering the overall market landscape.

A significant development from two years ago was Fujifilm Holdings' announcement in September 2021 regarding the initiation of clinical trials for a novel treatment targeting nontuberculous mycobacteria, further indicating progress in addressing this health concern.

## Report Scope

| MARKET SIZE 2024 | 350.55(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 360.33(USD Million) |
| MARKET SIZE 2035 | 474.3(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.79% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Becton Dickinson and Company (US), F. Hoffmann-La Roche AG (CH), bioMérieux SA (FR), Qiagen N.V. (NL), Hologic, Inc. (US) |
| Segments Covered | Class of Drugs |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection in the nontuberculous mycobacteria market. |
| Key Market Dynamics | Rising awareness of nontuberculous mycobacterial infections drives demand for advanced diagnostic and treatment solutions in Japan. |
| Countries Covered | Japan |

## Frequently Asked Questions

**Q: What was the market valuation of the Japan nontuberculous mycobacteria market in 2024?**
A: The market valuation was $350.55 Million in 2024.

**Q: What is the projected market valuation for the Japan nontuberculous mycobacteria market in 2035?**
A: The projected valuation for 2035 is $474.3 Million.

**Q: What is the expected CAGR for the Japan nontuberculous mycobacteria market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 2.79%.

**Q: Which companies are considered key players in the Japan nontuberculous mycobacteria market?**
A: Key players include Thermo Fisher Scientific, Merck KGaA, Abbott Laboratories, Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux SA, Qiagen N.V., and Hologic, Inc.

**Q: What are the main segments of the Japan nontuberculous mycobacteria market?**
A: Main segments include Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics.

**Q: What was the valuation of Oral Antibiotics in the Japan nontuberculous mycobacteria market?**
A: The valuation for Oral Antibiotics ranged from $100.0 Million to $130.0 Million.

**Q: How much did the Nebulized Antibiotics segment generate in 2024?**
A: The Nebulized Antibiotics segment generated between $120.55 Million and $174.3 Million.

**Q: What is the valuation range for IV Antibiotics in the market?**
A: The valuation for IV Antibiotics ranged from $80.0 Million to $100.0 Million.

**Q: What is the expected growth trend for the Japan nontuberculous mycobacteria market?**
A: The market is expected to grow steadily, reflecting the projected CAGR of 2.79% from 2025 to 2035.

**Q: What was the valuation for the Anti Nausea segment in 2024?**
A: The valuation for the Anti Nausea segment ranged from $50.0 Million to $70.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-nontuberculous-mycobacteria-market-52623*